Skip to main
MD

MEDNAX (MD) Stock Forecast & Price Target

MEDNAX (MD) Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 0%
Buy 25%
Hold 75%
Sell 0%
Strong Sell 0%

Bulls say

Pediatrix Medical Group Inc has demonstrated a solid performance in its financial results, reporting a 4.0% year-over-year same-unit revenue increase, primarily driven by a 6.7% growth in net reimbursement-related factors. The company benefits from a favorable reimbursement environment, which is further supported by improved birth rates, contractual wins with hospitals, and a favorable commercial payor mix, positioning it for continued revenue growth. Additionally, the strong balance sheet of Pediatrix enhances its financial stability and provides a foundation for potential strategic investments and capital deployment, contributing to a positive long-term outlook.

Bears say

Pediatrix Medical Group Inc reported total revenue of $493.8 million, which was slightly below expectations despite a year-over-year same-unit revenue growth of 6.7%, indicating potential challenges in patient volume with a decrease of 2.7%. The company is encountering downside risks such as sluggish same-unit trends, increased competition for mergers and acquisitions, a decline in birth rates, and heightened reimbursement risks that could adversely affect its financial stability. Additionally, adjusted EBITDA estimates remain unchanged for 2026 and 2027, but the lowered revenue forecasts reflect a concerning outlook for sustained growth, suggesting a need for strategic adjustments to navigate competitive pressures and health care market dynamics.

MEDNAX (MD) has been analyzed by 4 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 25% recommend Buy, 75% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MEDNAX and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MEDNAX (MD) Forecast

Analysts have given MEDNAX (MD) a Hold based on their latest research and market trends.

According to 4 analysts, MEDNAX (MD) has a Hold consensus rating as of Apr 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MEDNAX (MD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.